Stonepine Capital Management LLC Makes New $105,000 Investment in Elanco Animal Health Incorporated $ELAN

Stonepine Capital Management LLC acquired a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) during the 1st quarter, HoldingsChannel.com reports. The institutional investor acquired 10,000 shares of the company’s stock, valued at approximately $105,000.

Other institutional investors have also recently bought and sold shares of the company. Allworth Financial LP raised its holdings in Elanco Animal Health by 791.7% during the first quarter. Allworth Financial LP now owns 2,354 shares of the company’s stock worth $25,000 after buying an additional 2,090 shares during the last quarter. CoreCap Advisors LLC acquired a new position in Elanco Animal Health during the fourth quarter worth $29,000. Parallel Advisors LLC raised its holdings in Elanco Animal Health by 92.2% during the first quarter. Parallel Advisors LLC now owns 3,860 shares of the company’s stock worth $41,000 after buying an additional 1,852 shares during the last quarter. NBC Securities Inc. acquired a new position in Elanco Animal Health during the first quarter worth $40,000. Finally, Versant Capital Management Inc raised its holdings in Elanco Animal Health by 65.9% during the first quarter. Versant Capital Management Inc now owns 4,382 shares of the company’s stock worth $46,000 after buying an additional 1,740 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Wall Street Analyst Weigh In

ELAN has been the subject of several recent analyst reports. Piper Sandler upped their target price on shares of Elanco Animal Health from $12.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, August 11th. Wall Street Zen upgraded shares of Elanco Animal Health from a “hold” rating to a “buy” rating in a report on Saturday, July 5th. Stifel Nicolaus increased their target price on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company a “buy” rating in a report on Wednesday, July 2nd. Zacks Research downgraded shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a report on Wednesday. Finally, Leerink Partners upgraded shares of Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 target price for the company in a report on Thursday, July 17th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Elanco Animal Health has a consensus rating of “Moderate Buy” and an average price target of $17.33.

Elanco Animal Health Price Performance

ELAN opened at $17.8930 on Friday. The firm has a market cap of $8.89 billion, a P/E ratio of 20.81, a PEG ratio of 3.32 and a beta of 1.66. The firm has a 50-day moving average of $15.08 and a 200 day moving average of $12.47. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.40 and a current ratio of 2.60. Elanco Animal Health Incorporated has a fifty-two week low of $8.02 and a fifty-two week high of $18.08.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.06. The company had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.19 billion. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The firm’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.30 earnings per share. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. On average, research analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.